Timpani Capital Management’s Regenxbio RGNX Stock Holding History

Timpani Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-27,835	Closed	-$2.1M	–	97
2018 Q3	$2.1M	Buy	+27,835	New	+$2.01M	0.61%	61

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Timpani Capital Management's RGNX Position: Q4 2018 in Review

Timpani Capital Management sold out of Regenxbio (RGNX) in Q4 2018, closing a stake of 27,835 shares — an estimated $2.1M sold.

Timpani Capital Management first reported a position in RGNX in Q3 2018 and held it in 1 quarter. The position peaked at $2.1M in Q3 2018. 183 funds tracked by Wall St. Rank hold RGNX as of Q4 2018.

Timpani Capital Management reported no remaining Regenxbio position as of Q4 2018 after selling out during the quarter.
Timpani Capital Management sold 27,835 Regenxbio shares in Q4 2018, an estimated $2.1M.
Timpani Capital Management first reported a position in Regenxbio in Q3 2018 and held it in 1 quarter.
Timpani Capital Management's Regenxbio position peaked at $2.1M in Q3 2018.
183 funds tracked by Wall St. Rank held Regenxbio as of Q4 2018.

Based on Timpani Capital Management's 13F filing for Q4 2018, filed 11 Feb 2019.